

Federal Circuit Rules for Axinn Client in Tamiflu Patent Appeal

An abstract graphic on the right side of the header, featuring a light blue background with a grey grid pattern and a white, curved, ribbon-like shape.

NEWS | 1 MIN READ

April 25, 2014

HARTFORD, Conn.--(BUSINESS WIRE)--A ruling by the U.S. Court of Appeals for the Federal Circuit has given **Axinn** client **Natco Pharma Ltd.** a second chance at invalidating **Gilead Sciences Inc.'s** patent on the popular flu drug Tamiflu. The decision could pave the way to Natco's planned issuance of a generic version of the drug in the United States. Natco was represented by Axinn attorney [Thomas Hedemann](#).

The April 22 Federal Circuit ruling vacated a December 2012 district court ruling that Gilead did not unlawfully extend a patent covering Tamiflu and remanded the issue of the patent's validity back to the district court for reconsideration.

This is the first time the Federal Circuit has addressed whether a commonly-owned patent that issues after — but expires before — another patent can be rendered invalid for double-patenting. By ruling that it can, the court reaffirmed the double patenting doctrine, which prohibits inventors from unreasonably extending patent protection past the statutory limit.

The ruling also establishes a bright-line rule for patent practitioners and continues to provide inventors like Natco Pharma with the ability to use terminal disclaimers to overcome obviousness-type double patenting rejections.

In March, the U.S. Food and Drug Administration (USFDA) granted Natco tentative approval to sell its generic version of Tamiflu in the U.S. market. The approval, however, is contingent upon

Natco successfully resolving its patent dispute with Gilead Sciences.

Related People



Thomas K. Hedemann

Related Services

Intellectual Property

To subscribe to our publications, [click here](#).

Featured Insights

- GCR Live: Law Leaders Europe 2025
SPEAKING ENGAGEMENT ANTITRUST
- AHLA Annual Meeting 2025
SPEAKING ENGAGEMENT ANTITRUST
- SABA North America Annual Conference 2025
SPEAKING ENGAGEMENT ANTITRUST
- Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
WEBINAR ANTITRUST
- Volunteer Lawyers for the Arts – Champions of the Arts Awards and Gala 2025
SPONSORSHIP ANTITRUST

- NJSBA Annual Meeting and Convention 2025

SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY

- Cost-Effective and Efficient IP Litigation Strategies – Making Paragraph IV Litigation Work for You

WEBINAR INTELLECTUAL PROPERTY

- Hartford HealthCare Black and Red Gala 2025

SPONSORSHIP ANTITRUST

- Informa CompLaw Antitrust West Coast Conference 2025

SPEAKING ENGAGEMENT ANTITRUST

- Recent Decision Shows the Heavy Burden of Actual Malice in Defamation Suits

AXINN VIEWPOINTS LITIGATION & TRIALS

© 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved